Raydiant Oximetry Inc

Raydiant Oximetry is a clinical-stage medical device company developing innovative fetal monitoring technologies to improve maternal and neonatal outcomes during childbirth. The company's flagship product, Lumerah, is a non-invasive fetal pulse oximeter that measures fetal arterial blood oxygen saturation using biophotonics and machine learning—addressing a critical clinical need where current electronic fetal monitoring is associated with high false-positive rates and unnecessary cesarean deliveries. Lumerah has received FDA Breakthrough Device designation and completed a 35-patient Early Feasibility Study. The company also develops Daisy, a surgical device designed to quantify blood loss and prevent postpartum hemorrhage after cesarean sections. Raydiant Oximetry collaborates with GE HealthCare and has secured substantial funding including a $5.6 million Series A round and grants from the Bill & Melinda Gates Foundation and March of Dimes Innovation Fund. The company is positioned to reduce maternal and neonatal mortality while decreasing unnecessary emergency cesarean deliveries through evidence-based fetal oxygenation monitoring.